Treatment of infantile haemangiomas: recommendations of a European expert group
(2015) In European Journal of Pediatrics 174(7). p.855-865- Abstract
- With a prevalence of 2.6-4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. Conclusion: Oral propranolol is the first-line agent for the... (More)
- With a prevalence of 2.6-4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. Conclusion: Oral propranolol is the first-line agent for the treatment of complicated IH. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7596731
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Haemangioma, Complications, Therapy, Infants
- in
- European Journal of Pediatrics
- volume
- 174
- issue
- 7
- pages
- 855 - 865
- publisher
- Springer
- external identifiers
-
- wos:000356527900002
- scopus:84931562059
- pmid:26021855
- ISSN
- 1432-1076
- DOI
- 10.1007/s00431-015-2570-0
- language
- English
- LU publication?
- yes
- id
- 4ff47c2c-6901-44c0-8250-4812d7696dee (old id 7596731)
- date added to LUP
- 2016-04-01 10:45:29
- date last changed
- 2022-04-28 01:01:04
@article{4ff47c2c-6901-44c0-8250-4812d7696dee,
abstract = {{With a prevalence of 2.6-4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. Conclusion: Oral propranolol is the first-line agent for the treatment of complicated IH.}},
author = {{Hoeger, Peter H. and Harper, John I. and Baselga, Eulalia and Bonnet, Damien and Boon, Laurence M. and Degli Atti, Marta Ciofi and El Hachem, Maya and Oranje, Arnold P. and Troilius, Agneta and Weibel, Lisa and Leaute-Labreze, Christine}},
issn = {{1432-1076}},
keywords = {{Haemangioma; Complications; Therapy; Infants}},
language = {{eng}},
number = {{7}},
pages = {{855--865}},
publisher = {{Springer}},
series = {{European Journal of Pediatrics}},
title = {{Treatment of infantile haemangiomas: recommendations of a European expert group}},
url = {{http://dx.doi.org/10.1007/s00431-015-2570-0}},
doi = {{10.1007/s00431-015-2570-0}},
volume = {{174}},
year = {{2015}},
}